Courts uphold Biden’s IRA as pricing discussions progress

SEO Article Rewrite

A Legal Victory for Biden’s IRA

Pricing talks afoot, courts continue to support Biden's IRA

A recent ruling has dealt a significant blow to opponents of the Inflation Reduction Act (IRA), as a federal judge dismissed AstraZeneca’s attempt to halt price discussions for its diabetes drug Farxiga (dapagliflozin).

Market as Forxiga in Europe, this SGLT2 inhibitor was AstraZeneca’s top-performing product in 2023, generating close to $6 billion from its approved uses in chronic kidney disease, heart failure, and type 2 diabetes.

Access Exclusive Content

This article is only available to registered users. To continue reading, please register for free. A trial subscription grants you access to premium content, including interviews, round-ups, and expert opinions from industry leaders in pharmaceuticals and biotechnology for a week. If you are an existing user, kindly log in. To renew your trial, you can subscribe here.

Experience Before Committing

Get a taste of what we offer:

• Stay informed with the latest updates in pharma and biotech.
• Enjoy exclusive features, podcasts, interviews, data analysis, and insights from our global team of life sciences journalists.
• Receive The Pharma Letter daily news bulletin for free, forever.

Unlock Premium Features

Become a subscriber and enjoy:

• Full access to industry-leading news, analysis, and commentary in pharma and biotech.
• Stay updated on clinical trials, conferences, M&A, licensing, financing, regulations, patents & legal matters, executive appointments, commercial strategies, and financial results.
• Daily summaries of important events in the pharmaceutical and biotech sectors.
• Monthly detailed briefings on boardroom appointments and M&A updates.
• Choose between an affordable annual package or a flexible monthly subscription.

Read More of this Story at – 2024-03-04 16:45:30

Read More US Economic News

Leave A Reply

Your email address will not be published.